Medherant | Innovative transdermal drug delivery patches for women’s health

Medherant’s CEO, John Burt and Principal Scientist, Dr Gabit Nurumbetov, talk through its bespoke transdermal drug delivery patches and how it would be the only testosterone replacement patch available globally and could transform the lives of post-menopausal women suffering from loss of sex drive, if clinical trials later this year are successful.

Read more on Mercia’s latest investments here